Regenxbio Inc. (RGNX)
REGENXBIO Inc. (RGNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
REGENXBIO Inc. (RGNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Regenxbio: Remains A "Buy Rating" Despite BLA Review Delay Of RGX-121 For Hunter Syndrome
Regenxbio's RGX-121 for Hunter syndrome saw its FDA review delayed to February 8, 2026, but strong 12-month surrogate endpoint data supports its potential as a gene therapy. Late-stage Sura-vec trials for Wet-AMD, in partnership with AbbVie, remain on track for 2026 topline results, bolstering the pipeline's value. Recent partnerships and royalty deals have strengthened Regenxbio's cash position, extending its runway into early 2027 despite ongoing R&D expenses.
REGENXBIO Inc. (RGNX) Q2 2025 Earnings Call Transcript
REGENXBIO Inc. (NASDAQ:RGNX ) Q2 2025 Earnings Call August 7, 2025 8:00 AM ET Company Participants Curran M. Simpson - President, CEO & Director Mitchell Chan - Executive VP & CFO Patrick J.
Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates
Regenxbio (RGNX) came out with a quarterly loss of $1.38 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to a loss of $1.05 per share a year ago.
Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome
REGENXBIO specializes in gene therapies using proven AAV technology. RGX-121, targets Hunter syndrome and is under FDA review, with a PDUFA date set for November 9, 2025. We believe the upcoming FDA decision represents a significant catalyst for RGNX shares, offering a compelling pre-approval investment opportunity.
Regenxbio (RGNX) Q1 Earnings and Revenues Lag Estimates
Regenxbio (RGNX) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.41 per share. This compares to loss of $1.38 per share a year ago.
Regenxbio (RGNX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Regenxbio (RGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Reasons To Buy Regenxbio Right Now
Regenxbio Inc. is rated a "Strong Buy" due to many reasons reasons, some of those have nothing/little to do (directly) with pipeline or clinical trials. RGNX has an extremely low Enterprise Value, with potential for the EV to turn negative once upcoming scheduled/milestone payments and royalties come in. RGNX benefits from strategic partnerships, including $110M from Nippon Shinyaku and $200M from AbbVie, plus potential higher royalties from Novartis.
REGENXBIO Inc. (RGNX) Q4 2024 Earnings Call Transcript
REGENXBIO Inc. (NASDAQ:RGNX ) Q4 2024 Earnings Conference Call March 13, 2025 4:30 PM ET Company Participants Patrick Christmas - Chief Legal Officer Curran Simpson - President & Chief Executive Officer Steve Pakola - Chief Medical Officer Mitch Chan - Chief Financial Officer Conference Call Participants Judah Frommer - Morgan Stanley Gena Wang - Barclays Annabel Samimy - Stifel Brian Skorney - Baird Paul Choi - Goldman Sachs Ellie Merle - UBS Sean McCutcheon - Raymond James Alec Stranahan - Bank of America Yi Chen - H.C. Wainwright & Company Operator Welcome everyone to the Fourth Quarter and Year End 2024 REGENXBIO Earnings Conference Call.
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates
Regenxbio (RGNX) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $1.27. This compares to loss of $1.43 per share a year ago.
Will Regenxbio (RGNX) Report Negative Earnings Next Week? What You Should Know
Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns
Goldman Sachs downgraded Regenxbio Inc RGNX, citing gene therapy's appeal for wet AMD and diabetic retinopathy is uncertain, as most patients are elderly and newer anti-VEGF treatments offer longer-lasting effects at lower costs.
